ICAAC Highlights In Brief: The Liposome Company's ABLC

Executive Summary

The Liposome Company's ABLC: In a 231-patient Phase III study comparing ABLC (amphotericin B lipid complex) to conventional amphotericin B in patients with invasive candidiasis, nephrotoxicity is "significantly greater in patients receiving amphotericin B," investigators reported at ICAAC Sept. 18. "Baseline serum creatinine doubled in only 28% of ABLC patients compared to 47% of amphotericin B patients," Princeton, New Jersey-based TLC reports. "The median number of days before serum creatinine doubled was significantly (p=.028) shorter for the amphotericin B patients (19 days for amphotericin B versus 82 days for ABLC)." Response rates and mycological eradication rates for the two formulations were similar: 65% v. 61% and 88% v. 87% for ABLC and amphotericin B, respectively. TLC filed an NDA for ABLC for the treatment of aspergillosis in May...